Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.
High-resolution computed tomography shows evidence of ILD.
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
2026 Medicare Physician Fee Schedule Proposed Rule Released
The proposed rule includes several proposals related to Medicare physician payment and the Quality Payment Program. Read more about the provisions the ACR will address during the comment period.
Connect with Your Lawmakers During the August Recess
August offers an opportunity to engage with your elected officials in your state or district. Lawmakers will be considering appropriations bills when they return in September—help make sure the needs of the rheumatology community are top of mind.
ACR Garners Major Media Attention Following Response to Proposed 2026 Physician Fee Schedule
The ACR’s press release expressed disappointment about the proposed rule not going far enough to fix Medicare payment for physicians. Substantial media coverage of the response resulted in a combined reach of over 6.1 million people, amplifying the ACR’s voice and advocacy efforts.
Finding the Panacea
Janus kinase (JAK) inhibitors, biologics and more—Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.
New Study: Upadacitinib Is Treatment Option for Giant Cell Arteritis
Results of the international SELECT-GCA study suggest that upadacitinib may be an effective new oral treatment for giant cell arteritis.
ACR Urges Strong AI Safeguards in State Model Legislation
In comments to the National Association of Insurance Commissioners, the ACR outlined several recommendations for a proposed state model law addressing the use of artificial intelligence in the insurance industry.
RheumPAC Fundraising Update: Q2
As of the close of the second quarter of CY2025, RheumPAC has raised $51,865 from 141 ACR members.
ACR-Led Resolutions Supporting Research Funding, Biosimilars Access Advance at Annual AMA House of Delegates Meeting
An ACR-led resolution that calls for the protection of NIH funding and the ability to negotiate indirect costs will become AMA policy, along with several other resolutions supported by the ACR.
Executive Order Ties U.S. Drug Prices to Lowest Global Rates
In May, the Trump administration published an executive order requiring drug companies to bring prices in line with those paid by other developed nations, otherwise known as Most Favored Nation (MFN) pricing. Although the June 11 deadline has come and gone, no details have been released as to whether drug companies have opted to negotiate or if the government will implement any enforcement action.
- 1
- 2
- 3
- …
- 244
- Next Page »